Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"CPDC Centre for Probe Development and Commercialization","sponsor":"CellBion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Centre for Probe Development and Commercialization Expands Into Asia and Executes a Development, Manufacturing, and Clinical Supply Agreement For 177Lu-PSMA (DGUL) With South Korea-based CellBion","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CPDC Centre for Probe Development and Commercialization","sponsor":"Isotopia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by CPDC Centre for Probe Development and Commercialization

    Menu

    CPDC Centre for Probe Development and Commercialization

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              CPDC Centre for Probe Development and Commercialization

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers

              Details:

              177Lu n.c.a (No-carrier-added Lutetium-177) is a very versatile isotope, and worldwide numerous clinical trials are being held, studying the effects of this isotope, used radiometal for targeted radiotherapy.

              Lead Product(s): No-Carrier-Added Lutetium-177

              Therapeutic Area: Oncology Product Name: n.c.a 177 Lu

              Highest Development Status: Undisclosed Product Type: Small molecule

              Recipient: Isotopia

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CPDC Centre for Probe Development and Commercialization

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              The Centre for Probe Development and Commercialization Expands Into Asia and Executes a Development, Manufacturing, and Clinical Supply Agreement For 177Lu-PSMA (DGUL) With...

              Details:

              Under the terms of the agreement, CPDC will develop and manufacture CellBion's drug product Lu-177-PSMA-D GUL, for Phase II clinical supply in South Korea with the goal of expanding into North America.

              Lead Product(s): Lu-177-PSMA-D GUL

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: CellBion

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY